Keyphrases
Hodgkin Lymphoma
100%
Brentuximab Vedotin
100%
Safety Assessment
100%
Antibody-drug Conjugate
20%
Clinical Trials
10%
Adverse Events
10%
Neutropenia
10%
Relapsed or Refractory
10%
Peripheral Neuropathy
10%
Phase I Study
10%
Standard of Care
10%
Treatment Duration
10%
Safety Data
10%
Phase II Trial
10%
Early Disease
10%
Expert Opinion
10%
Line of Therapy
10%
Bleomycin
10%
Toxicity Profile
10%
CD30
10%
Therapeutic Monoclonal Antibody
10%
Area Cover
10%
Lymphoma Therapy
10%
Combination Regimen
10%
Pulmonary Toxicity
10%
Frontline Therapy
10%
Relapsed Lymphoma
10%
Refractory Hodgkin Lymphoma
10%
Optimal Duration
10%
Pivotal Trial
10%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Brentuximab Vedotin
100%
Antibody Drug Conjugate
20%
Clinical Trial
10%
Neutropenia
10%
Adverse Event
10%
Side Effect
10%
Neuropathy
10%
Bleomycin
10%
Lung Toxicity
10%
Sgn 30
10%
Diseases
10%